Key facts
- This page summarizes Brendan P. O'Grady's Form 4 filing for Nasus Pharma Ltd (NSRX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Nov 2026, 19:35.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Options to purchase 210,000 ordinary shares of the Issuer, no par value ("Ordinary Shares"), were granted on July 27, 2026, with one-third of such options, representing 70,000 options, vesting on July 27, 2027, and the remaining two-thirds vesting in eight equal quarterly installments of 17,500 options, beginning on October 27, 2027. The foregoing options are part of the reporting person's compensation package as the Chief Executive Officer of the Issuer, which was approved by the Issuer's shareholders on October 8, 2026.
Footnote F2
Of the 210,000 options reported herein, the first one-third, representing 70,000 options, will be exercisable at $3.50 per Ordinary Share, the second one-third, representing 70,000 options, will be exercisable at $4.25 per Ordinary Share, and the final one-third, representing 70,000 options, will be exercisable at $5.00 per Ordinary Share; provided that the exercise price of an option may not be less than the Fair Market Value of an Ordinary Share, as defined pursuant to the Issuer's 2019 Incentive Option Plan, including, without limitation, the Sub-Plan for U.S. Persons, on the grant date.